End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.99 CNY | +1.06% | +2.67% | -9.67% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.67% | 5.06B | C- | ||
-2.61% | 89.08B | A- | ||
+3.55% | 40.9B | A- | ||
-14.40% | 32.25B | B- | ||
+55.89% | 25.14B | A | ||
-15.96% | 15.39B | C | ||
-15.50% | 11.91B | B- | ||
-41.29% | 11.89B | B | ||
-11.75% | 11.64B | D+ | ||
+7.87% | 9.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002007 Stock
- Ratings Hualan Biological Engineering Inc.